Post‐licensure safety surveillance for human papillomavirus‐16/18‐AS04‐adjuvanted vaccine: more than 4 years of experience-Reference-Cited by-同舟云学术

Post‐licensure safety surveillance for human papillomavirus‐16/18‐AS04‐adjuvanted vaccine: more than 4 years of experience

Published:2014-02-20 Issue:5 Volume:23 Page:456-465
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Angelo Maria‐Genalin¹,Zima Julia¹,Tavares Da Silva Fernanda¹,Baril Laurence¹,Arellano Felix¹

Affiliation:

1. GlaxoSmithKline Vaccines Wavre Belgium

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.3593

Reference39 articles.

1. Safety of Human Papillomavirus Vaccines: A Review

2. Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization.2012.http://www.meddramsso.com/(accessed 21 November 2012).

3. Report of CIOMS Working Group IV.Benefit–risk balance for marketed drugs: evaluating safety signals.1998.http://www.cioms.ch/publications/g4‐benefit‐risk.pdf(accessed 21 November 2012).

4. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

5. Cervarix Summary of Product Characteristics.2012.http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac058001d124(accessed 21 November 2012).

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety profile assessment of HPV4 and HPV9 vaccines through the passive surveillance system of the Veneto Region (Italy) between 2008 and 2022: A 15-year retrospective observational study;Vaccine: X;2024-08

2. Aluminum oxyhydroxide-Poly(I:C) combination adjuvant with balanced immunostimulatory potentials for prophylactic vaccines;Journal of Controlled Release;2024-08

3. Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis;Vaccine;2023-06

4. Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017–2021);Human Vaccines & Immunotherapeutics;2023-01-02

5. Human Papillomavirus Vaccines;Plotkin's Vaccines;2023